EUCTR2010-023498-20-PL进行中（未招募）不适用
Assessment of the Pharmacokinetics of Boceprevir in Pediatric Subjects with Chronic Hepatitis C Genotype 1 (Phase 1b)
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 48
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Subject must be 17 to 3 years of age (inclusive) at screening.
- •2. Each subject must have previously documented CHC genotype 1 infection.
- •Subjects with other or mixed genotypes are not eligible. The HCV-RNA result at the Screening visit must confirm genotype 1 infection.
- •3. Subject may be treatment naïve, or failed previous (peg)interferon/RBV treatment and may be cirrhotic or non-cirrhotic.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 48
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Key Clinical Exclusion Criteria:
- •1. Subject known to be co-infected with the human immunodeficiency virus (HIV) and hepatitis B virus (HBsAg positive).
- •2. Subject received treatment with RBV within 90 days or any interferon-alpha
- •within 30 days prior to screening, or currently be receiving antiviral / immunomodulatory treatment for hepatitis C.
- •3. Subject must not have received previous treatment with a HCV protease inhibitor.
- •Key Clinical Laboratory Criteria:
- •Hematologic criteria (growth factors may not be used to achieve study entry requirements):
- •o Hemoglobin < lower limit of normal range (LLN)
- •o Neutrophils <1500/mm3
- •o Platelets <100,000/mm3
- •Serum albumin < lower limit of normal (LLN) of laboratory reference range.
- •Thyroid-stimulating hormone (TSH) >1.2 x ULN or <0.8 x LLN of laboratory reference range with the following exceptions:
- •o The subject may be enrolled if clinically euthyroid, AND
- •o The euthyroid function is confirmed by thyroxine/triiodothyronine (T4/T3) testing
- •Serum creatinine > ULN of laboratory reference range
研究者
相似试验
进行中（未招募）
不适用
A single dose study of boceprevir in children and adolescents to determine the therapeutic dose.Hepatitis type C (genotype I) virus infectionMedDRA version: 14.1Level: PTClassification code 10019744Term: Hepatitis CSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 14.1Level: LLTClassification code 10008912Term: Chronic hepatitis CSystem Organ Class: 10021881 - Infections and infestationsEUCTR2010-023498-20-GBMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.48
进行中（未招募）
不适用
A single dose study of boceprevir in children and adolescents to determine the therapeutic dose.EUCTR2010-023498-20-DEMerck Sharp & Dohme Corp., a subsidiary of Merck and Co., Inc.48
进行中（未招募）
不适用
A single dose study of boceprevir in children and adolescents to determine the therapeutic dose.Hepatitis type C (genotype I) virus infectionMedDRA version: 14.1Level: LLTClassification code 10008912Term: Chronic hepatitis CSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 14.1Level: PTClassification code 10019744Term: Hepatitis CSystem Organ Class: 10021881 - Infections and infestationsEUCTR2010-023498-20-ESMerck Sharp & Dohme Corp., a subsidiary of Merck & Co.,Inc.48
终止
1 期
Pharmacokinetics of Boceprevir in Pediatric Subjects With Chronic Hepatitis C Genotype 1 (P07614)Hepatitis C, ChronicNCT01425190Merck Sharp & Dohme LLC16
进行中（未招募）
1 期
A Phase 3 Safety and Efficacy Study of Boceprevir in Subjects With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon/RibaviriChronic Hepatitis CMedDRA version: 9.1 Level: LLT Classification code 10008912 Term: Chronic hepatitis CMedDRA version: 9.1 Level: PT Classification code 10019744 Term: Hepatitis CMedDRA version: 9.1 Level: SOC Classification code 10021881 Term: Infections and infestationsMedDRA version: 9.1 Level: SOC Classification code 10019805 Term: Hepatobiliary disordersEUCTR2007-005151-42-FRSchering Plough Research Institute, A Division of Schering Corporation375